International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The revised diagnostic criteria for multiple myeloma and smoldering multiple myeloma have been proposed by the International Myeloma Working Group. These criteria include specific requirements for bone marrow plasma cells, serum free light chain ratio, MRI findings, myeloma bone disease, renal failure, monoclonal protein, and the need for symptoms. The updated criteria aim to improve the accuracy of diagnosis and identify high-risk patients who may benefit from early intervention. The use of validated biomarkers and imaging techniques, such as multiparametric flow cytometry and next-generation sequencing, may provide additional prognostic information and help guide treatment decisions. The development of new therapies, such as lenalidomide and bortezomib, has improved outcomes for patients with multiple myeloma. The use of combination therapies and novel agents has also shown efficacy in the treatment of newly diagnosed and relapsed or refractory multiple myeloma. High-dose chemotherapy followed by autologous stem cell transplantation remains a standard treatment option for eligible patients. The presence of renal impairment, monoclonal gammopathy-associated proliferative glomerulonephritis, and other plasma cell disorders can impact prognosis and treatment decisions. The identification of high-risk patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma is important for determining appropriate management and treatment strategies. The implementation of the updated diagnostic criteria and the use of biomarkers in routine practice and future clinical trials are recommended by the International Myeloma Working Group.
Important Points:
- Criteria include requirements for bone marrow plasma cells, serum free light chain ratio, MRI findings, myeloma bone disease, renal failure, monoclonal protein, and symptoms.
- Aim to improve accuracy of diagnosis and identify high-risk patients.
- Use of validated biomarkers and imaging techniques may provide additional prognostic information.
- Development of new therapies, such as lenalidomide and bortezomib, has improved outcomes.
- Combination therapies and novel agents have shown efficacy in newly diagnosed and relapsed or refractory multiple myeloma.
- High-dose chemotherapy followed by autologous stem cell transplantation is a standard treatment option.
- Presence of renal impairment, monoclonal gammopathy-associated proliferative glomerulonephritis, and other plasma cell disorders can impact prognosis and treatment decisions.
- Identification of high-risk patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma is important.
- Implementation of updated diagnostic criteria and use of biomarkers in routine practice and future clinical trials is recommended.
Authors:
S. Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, Maria-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson, Ola Landgren, Bruno Paiva, Angela Dispenzieri, Brendan Weiss, Xavier LeLeu, Sonja Zweegman, Sagar Lonial, Laura Rosinol, Elena Zamagni, Sundar Jagannath, Orhan Sezer, Sigurdur Y Kristinsson, Jo Caers, Saad Z Usmani, Juan Jose Lahuerta, Hans Erik Johnsen, Meral Beksac, Michele Cavo, Hartmut Goldschmidt, Evangelos Terpos, Robert A Kyle, Kenneth C Anderson, Brian G.M. Durie, Jesus F. San Miguel
Citation:
Lancet Oncol 2014; 15: e538–48
https://doi.org/10.1016/S1470-2045(14)70442-5